Torrent Pharmaceuticals has removed three key executives from its Senior Management Personnel (SMP) roster, signaling an internal restructuring of its reporting hierarchy. Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni ceased to hold SMP designations effective July 30, 2026, at close of business hours. The company clarified that this change stems from a modification in the internal reporting structure rather than resignations or removals from their respective roles within the organization.

The intimation was issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure was signed by Chintan M. Trivedi, Company Secretary, and submitted to both the Bombay Stock Exchange and the National Stock Exchange of India Ltd.

Changes in Senior Management Designation

The filing specifies that all three individuals retained their positions within the company but were delisted from the specific regulatory category of Senior Management Personnel. This distinction is critical for compliance purposes, as SMPs are subject to specific insider trading codes and disclosure requirements under SEBI regulations.

The simultaneous nature of these changes suggests a broader organizational realignment rather than isolated personnel adjustments. The company did not provide details on who assumes the SMP responsibilities previously held by these executives, nor did it specify their new reporting lines.

What This Means for Governance

The reduction in the number of designated SMPs may streamline decision-making protocols but could also concentrate compliance responsibilities among fewer individuals. Investors and regulators will monitor whether this structural change impacts the company’s internal controls or insider trading surveillance mechanisms. The move reflects Torrent Pharmaceuticals’ ongoing efforts to optimize its corporate governance framework in alignment with evolving operational needs.

Torrent Pharmaceuticals reported a consolidated net profit of ₹566 crore for the quarter ended June 30, 2026, marking a 3% increase from ₹548 crore in the same period last year. Consolidated revenue from operations surged 55% year-on-year to ₹4,921 crore, significantly boosted by the inclusion of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) following its amalgamation with effect from January 21, 2026. The company's operational EBITDA rose 61% to ₹1,664 crore, with a margin of 33.81% compared to 32.47% in the year-ago period. The Board of Directors approved the unaudited standalone and consolidated financial results on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The statutory auditors, B S R & Co. LLP, issued a limited review report on the financial statements pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations. The audit concluded that nothing came to their attention to cause them to believe that the statement had not disclosed all required information or contained any material misstatement. The comparative figures for the quarter and year ended March 31, 2026, have been restated to reflect the pooling of interest method accounting for the JB Pharma merger, as approved by the National Company Law Tribunal (NCLT) on July 6, 2026.

Financial Performance Breakdown

The consolidated revenue surge was underpinned by robust performance across both the base business and the newly integrated JB Pharma segment. The base business generated revenues of ₹3,720 crore, representing a 17% organic growth year-on-year. The JB Pharma segment contributed ₹1,201 crore, up 10% compared to the prior year's corresponding period. Standalone revenue reached ₹4,158 crore, up from ₹2,616 crore in Q1FY26, with standalone net profit standing at ₹492 crore.

The table below summarises the key consolidated financial metrics for the quarter:

*Before exceptional items

Exceptional items impacted the bottom line by ₹21 crore in Q1FY27. This included ₹2 crore towards regulatory and statutory fees associated with the JB Pharma acquisition, and a ₹19 crore inventory write-off due to a fire incident at an erstwhile JB Pharma warehouse. The company noted that no effect has been given to the related insurance claim, which remains under assessment. Additionally, severance compensation of ₹19 crore was recorded in the previous fiscal year related to the restructuring of JB Pharma's distribution network.

Regional Business Highlights

The India business delivered record high organic growth, with revenues reaching ₹2,157 crore, up 19% year-on-year against an IPM market growth of 12%. Torrent secured the top rank in the Indian cardiac market and saw its generic Semaglutide product achieve a 36% market share in Q1FY27. Internationally, US revenues grew 36% to ₹418 crore, driven by new launches. Brazil revenues increased 27% to ₹277 crore, although the company undertook a one-time channel inventory reduction due to credit period requests amid rising interest costs. Germany revenues remained flat at ₹318 crore, impacted by supply disruptions.

What the Numbers Show

The significant divergence between the 55% revenue growth and the modest 3% net profit growth highlights the capital-intensive nature of the recent expansion. While operational efficiency improved with EBITDA margins expanding to 33.81%, the integration costs and exceptional items dampened the bottom-line impact. The debt equity ratio stood at 0.82 times for the consolidated entity, reflecting the substantial leverage taken to fund the JB Pharma acquisition. However, the debt service coverage ratio remains healthy at 3.98 times, indicating sufficient cash flow to meet debt obligations despite the increased borrowings.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE685A01028/21f4885435a84428.pdf